Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: The open-label randomized phase III trial JCOG0505

Journal of Clinical Oncology

Volumn 33, Issue 19, 2015, Pages 2129-2135

  Kitagawa, Ryo ^a   Katsumata, Noriyuki ^d   Shibata, Taro ^b   Kamura, Toshiharu ^e   Kasamatsu, Takahiro ^c   Nakanishi, Toru ^f   Nishimura, Sadako ^g   Ushijima, Kimio ^e   Takano, Masashi ^h   Satoh, Toyomi ⁱ   Yoshikawa, Hiroyuki ⁱ  

^a Kanto Teishin Hospital   (Japan)

^b NATIONAL CANCER CENTER   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

^d NIPPON MEDICAL SCHOOL MUSASHI KOSUGI HOSPITAL   (Japan)

^e KURUME UNIVERSITY   (Japan)

^f AICHI CANCER CENTER HOSPITAL   (Japan)

^g OSAKA CITY GENERAL HOSPITAL   (Japan)

^h NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

ⁱ UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT;

ADULT; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MORTALITY; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; THROMBOCYTOPENIA; UTERINE CERVIX CANCER; VOMITING; CLINICAL TRIAL; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; QUALITY OF LIFE; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CISPLATIN; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL; QUALITY OF LIFE; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 84937422385     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.58.4391     Document Type: Article

References (30)

1. Friedlander M, Grogan M: Guidelines for the treatment of recurrent and metastatic cervical cancer. Oncologist 7:342-347, 2002
2. Thigpen JT, Vance R, Puneky L, et al: Chemotherapy as a palliative treatment in carcinoma of the uterine cervix. Semin Oncol 22:16-24, 1995 (suppl 3)
3. Moore DH, Blessing JA, McQuellon RP, et al: Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study. J Clin Oncol 22:3113-3119, 2004
4. Monk BJ, Sill MW, McMeekin DS, et al: Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: A Gynecologic Oncology Group study. J Clin Oncol 27:4649-4655, 2009
5. Calvert AH, Harland SJ, Newell DR, et al: Early clinical studies with cis-diammine-1, 1-cyclobutane dicarboxylate platinum II. Cancer Chemother Pharmacol 9:140-147, 1982
6. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, et al: European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion. J Clin Oncol 12:2654-2666, 1994
7. Arseneau J, Blessing JA, Stehman FB, et al: A phase II study of carboplatin in advanced squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study. Invest New Drugs 4:187-191, 1986
8. Weiss GR, Green S, Hannigan EV, et al: A phase II trial of carboplatin for recurrent or metastatic squamous carcinoma of the uterine cervix: A Southwest Oncology Group study. Gynecol Oncol 39:332-336, 1990
9. McGuire WP 3rd, Arseneau J, Blessing JA, et al: A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix: A Gynecologic Oncology Group study. J Clin Oncol 7:1462-1468, 1989
10. Anderson H, Wagstaff J, Crowther D, et al: Comparative toxicity of cisplatin, carboplatin (CBDCA) and iproplatin (CHIP) in combination with cyclophosphamide in patients with advanced epithelial ovarian cancer. Eur J Cancer Clin Oncol 24:1471-1479, 1988
11. Kitagawa R, Katsumata N, Ando M, et al: A multi-institutional phase II trial of paclitaxel and carboplatin in the treatment of advanced or recurrent cervical cancer. Gynecol Oncol 125:307-311, 2012
12. Saito I, Kitagawa R, Fukuda H, et al: A phase III trial of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in stage IVB, persistent or recurrent cervical cancer: Gynecologic Cancer Study Group/Japan Clinical Oncology Group study (JCOG0505). Jpn J Clin Oncol 40:90-93, 2010
13. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organisation for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
14. Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982
15. Calvert AH, Newell DR, Gumbrell LA, et al: Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748-1756, 1989
16. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41, 1976
17. Schoenfeld DA, Richter JR: Nomograms for calculating the number of patients needed for a clinical trial with survival as an endpoint. Biometrics 38:163-170, 1982
18. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
19. Brader KR, Morris M, Levenback C, et al: Chemotherapy for cervical carcinoma: Factors determining response and implications for clinical trial design. J Clin Oncol 16:1879-1884, 1998
20. Potter ME, Hatch KD, Potter MY, et al: Factors affecting the response of recurrent squamous cell carcinoma of the cervix to cisplatin. Cancer 63:1283-1286, 1989
21. Royston P, Parmar MK: Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modeling and estimation of treatment effects. Stat Med 21:2175-2197, 2002
22. Early Breast Cancer Trialists' Collaborative Group: Introduction and Methods in Treatment of Early Breast Cancer: Worldwide Evidence 1985-1990 (volume 1). Oxford, United Kingdom, Oxford University Press, 1990
23. Lan KKG, DeMets DL: Discrete sequential boundaries for clinical trials. Biometrika 70:659-663, 1983
24. Long HJ 3rd, Bundy BN, Grendys EC Jr, et al: Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: A Gynecologic Oncology Group study. J Clin Oncol 23:4626-4633, 2005
25. Kuo DY, Blank SV, Christos PJ, et al: Paclitaxel plus oxaliplatin for recurrent or metastatic cervical cancer: A New York Cancer Consortium study. Gynecol Oncol 116:442-446, 2010
26. Rabik CA, Dolan ME: Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 33:9-23, 2007
27. Tewari KS, Sill MW, Long HJ 3rd, et al: Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 370:734-743, 2014
28. Tinker AV, Bhagat K, Swenerton KD, et al: Carboplatin and paclitaxel for advanced and recurrent cervical carcinoma: The British Columbia Cancer Agency experience. Gynecol Oncol 98:54-58, 2005
29. Pectasides D, Fountzilas G, Papaxoinis G, et al: Carboplatin and paclitaxel in metastatic or recurrent cervical cancer. Int J Gynecol Cancer 19:777-781, 2009
30. Ozols RF, Bundy BN, Greer BE, et al: Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 21:3194-3200, 2003